Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Zenalux Announces Research Partnership Program for the Development of New Optical Spectroscopy AppliZenascope™ effectively and non-destructively monitors key tissue biomarkers in real-time…
By: Zenalux Zenascope™ uses standard spectroscopic measurement hardware, proprietary software, and patented algorithms to achieve rapid, quantitative, and non-destructive analysis of biological tissue characteristics (biomarkers) “Zenascope is a revolutionary tool that can confidently and easily be used to monitor tissue properties,” The base Zenascope is designed to measure blood concentration, blood oxygen saturation and scattering (a measure of cell density) in various mouse models. However, the system can be easily customized to other tissues and absorbers including, for example, beta-carotene in the breast and melanin in skin. The purpose of the Research Partner Program is to build collaborations between Zenalux and researchers or clinicians who wish to customize the Zenascope for their specific applications. A number of pre-clinical and clinical studies have already demonstrated the efficacy of this quantitative diagnostic technique, such as: · In vivo head and neck study – statistically significant differences in oxygen saturation and oxygenated hemoglobin were identified between malignant and nonmalignant tissues; · In vivo breast study - showed diffuse reflectance spectroscopy as a quantitative tool to measure oxygenation levels in the vascular compartment of breast cancers in vivo via an optical biopsy technique; · Pre-clinical head and neck study - the optically derived and immunohistochemical end points in animals with 4T1 tumors showed that the temporal kinetics of dHb concentration and < μ s ′ > were highly concordant with those of hypoxic and necrotic fractions, respectively; · Cervical study - optical spectroscopy is capable of detecting absorption and scattering contrast in the cervix; and · Breast tumor margin assessment - performance metrics of the system match clinical criteria for margin assessment (sufficient SNR, low errors in extraction of optical properties, low crosstalk). The Zenalux system achieves rapid, quantitative, and non-destructive analysis of the following biological endpoints: oxy-hemoglobin concentration ([HBO2]); deoxy-hemoglobin concentration ([HHb]); total hemoglobin concentration (THC); blood saturation (SO2); and scatterer size and density. The Zenalux Research Partner Program offers qualified organizations system and software support for the development and validation of unique applications of the Zenascope platform. Zenascope is currently designated for investigational purposes only. Interested organizations can contact Zenalux at info@zenalux.com or 919-794-5757. About Zenalux Biomedical, Inc. Zenalux Biomedical is a biomedical diagnostics start-up company that is developing novel biophotonic- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|